Bifeprunox mesilate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBifeprunox mesilate
Drug Alias Namebifeprunoxum联苯芦诺bifeprunoxDU-127090
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsDopamine D2 receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderSchizophreniaConduct Disorder +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[31] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcH. Lundbeck A/SSolvay Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsBipolar I DisorderSchizophreniaConduct Disorder +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG